USSTOCK.TODAY
Pre-Market
Log in Sign up

Madrigal Pharmaceuticals shares fall ahead of Q3 earnings release

Earnings Whispers · ·by G4L

MDGL
MDGL Madrigal Pharmaceuticals Inc
$432.60 -0.04%
View chart & analysis →
  1. 1Madrigal Pharmaceuticals shares have fallen 14.1% since the last report.
  2. 2Madrigal Pharmaceuticals' active patient count exceeded 50,000 in July.
  3. 3ResDifera recorded cumulative revenue of approximately $1.3 billion.

So what's the key point?

Madrigal Pharmaceuticals' stock price dropped by about 14.1%. Even though the patient count passed 50,000 and revenue reached $1.3 billion, the stock price went down.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Madrigal Pharmaceuticals Achieves First Profitable Quarter and Revenue Growth Earnings Whispers · 6d agoMediWound to Proceed with EscharEx Phase 3 Clinical Trials and Comparison with Madrigal Pharmaceuticals Case FinanceWire · Nov 3Paramount weighs selling CNN to clear $110B Warner acquisition GuruFocus.com +4 · Aug 14
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news